BACKGROUND: Cardiovascular disease (CVD) is considered to be the main cause of death and one of the most common diseases affecting health care systems worldwide. Many methods have been used to improve CVD outcomes, one of which is to involve clinical pharmacists in the direct care of patients with CVD.
• Cardiovascular disease (CVD) is one of the main causes of death worldwide and is associated with high cost impact on national economies through direct health costs, productivity losses, and informal health care costs.
• The quality of care of CVD patients has been reported to be suboptimal.
What is already known about this subject
• Clinical pharmacist interventions in the care of patients with CVD or in the care of those with high risks have been evaluated in several studies. Koshman et al. (2008) conducted a systematic review to measure the clinical benefit of adding a clinical pharmacist to the care of patients with heart failure in both inpatient and outpatient settings worldwide. This review demonstrated an improvement for many outcomes, including mortality and hospitalization.
• The current study is the first systematic review to evaluate pharmacist interventions in coronary heart disease (CHD) and heart failure and to evaluate the effect of pharmacist intervention in the prevention of CVD risk factors whether as part of primary prevention or secondary prevention.
• Pharmacist intervention resulted in greater improvements in many outcomes than using usual care only.
• This review highlights the need for further studies to evaluate pharmacist intervention in secondary prevention of CHD in inpatient settings and for a full economic evaluation investigating the cost-effectiveness of health care services in this setting.
What this study adds
C ardiovascular disease (CVD) is considered to be the main cause of death worldwide. 1 In 2008, CVD was responsible for about 48% of the 36 million deaths worldwide. 1 Similar percentages were also found in countries with advanced health care systems. CVD accounted for 33.4% of deaths in the United States, 34% in the United Kingdom (UK), and in Europe, the percentage increased to close to half of all deaths (48%). 2, 3 CVD is also considered the main cause of premature death in people under 70 worldwide, being responsible for about 39% of those reported deaths. 1 The main forms of CVD are coronary heart disease (CHD) and heart failure (HF). The National Institute for Health and Clinical Excellence (NICE) defined CHD as "a narrowing (stenosis) of the coronary arteries as a result of deposition of atherosclerotic plaque, which results in an insufficient supply of oxygen to the heart muscle. 4 NICE also defined HF as "a complex clinical syndrome of symptoms and signs that suggest the efficiency of the heart as a pump is impaired. It is caused by structural or functional abnormalities of the heart." 5 CHD by itself is 
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of patients with CVD. The scope of our review focused on the 2 main forms of CVD: CHD and HF. A comprehensive, systematic review was conducted of studies that evaluate the effects of clinical pharmacist intervention within a multidisciplinary team in the secondary prevention of CVD. Since the secondary prevention of CHD requires modification of risk factors in addition to secondary prevention medication, this review will consider the impact of clinical pharmacists in both areas, as well as their role in HF treatment. Since the intervention provided by clinical pharmacists to help control CVD risk factors is the same in primary and secondary prevention of CVD, we included studies evaluating the pharmacist effect in controlling CVD risk factors in both primary and secondary prevention. We included CVD risk factors that necessitate medication prescription in order to control them, such as hypertension, high cholesterol, diabetes mellitus (DM), and cigarette smoking.
■■ Methods
We searched the following databases in February 2011 (with no time limitation included): Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effectiveness (DARE), Health Technology Assessment Database (HTA), MEDLINE/PubMed, Web of Knowledge, HMIC (Ovid), Cumulative Index to Nursing and Allied Health Literature (CINAHL) plus search engine, National Health Service (NHS) Evidence, Science Direct, Pharmacy Abstract, National Institute for Health's Clinical Trials.gov database, Trip database, and Current Controlled Trials (CCT; Appendix A, available online). Systematic reviews and meta-analyses were excluded because their inclusion and exclusion criteria may not have been in accord with our criteria, although their bibliographies and references were searched for additional articles that may not have been captured in our electronic database search. The results were limited to published studies in English.
Inclusion and Exclusion Criteria
We included studies if they (a) involved participants who received direct care from a clinical pharmacist in the CVD therapeutic area or for CVD risk factors; (b) described pharmacist intervention as a part of a multidisciplinary team, in collaboration with other health care workers or in disease-led management in direct patient care; (c) reported 1 of the following outcomes: CVD control or mortality, CVD risk factor control, patient-related outcomes (knowledge, adherence, or quality of life), or cost related to health care systems; (d) were randomized controlled trials (RCT); and (e) conducted in inpatient, outpatient, or community settings. Nonrandomized controlled trials (non-RCT) reporting costs and patient quality of life were described but not included in the synthesis. The description of these non-RCTs helped explain differences found in the cost or quality of life. We excluded studies that had no pharmacist involvement in service or intervention and that were responsible for about 12.7% of all deaths, while it is considered to be the main cause of death in the UK, where 46% of all CVD deaths were due to CHD. On the other hand, HF is responsible for about 5% of all hospital admissions in Europe, with 40% of these admissions dying or being re-admitted within 1 year, 6 and represents a large proportion of treatment costs. For example, a U.S. report showed that HF admissions constitute about 60% of the total treatment costs. 7 CVD also has a significant economic impact through direct health care costs, productivity losses, and informal health care costs. It has been estimated that in the UK CVD costs the health care system approximately £8.7 billion and that 23% of this cost was due to medication prescribing. 8 In the United States, CVD was estimated to cost the health care system around $167 billion. 3 Newly developed medications are designed to be more potent with precise mechanism of action. These require more attention to avoid potential inappropriate prescribing that can lead to an increase in the CVD treatment cost. The traditional method of prescribing and dispensing has proved insufficient to prevent costly consequences from improper medication use. 9 Furthermore, despite efforts made to optimize therapies through published CVD treatment guidelines, the adherence to guideline recommendations is relatively low, and the quality of care provided to patients is documented to be below the target level.
10, 11 The presence of a clinical pharmacist can help decrease these problems and optimize patient therapy so as to achieve greater benefits. 12 The European Society of Clinical Pharmacy defines the role of a clinical pharmacist as one that "develop[s] and promote [s] safe and appropriate drug use with the goal of optimizing patient care." 13 The American College of Clinical Pharmacy defines clinical pharmacy as a "health science discipline in which pharmacists provide patient care that optimizes medication therapy and promotes health, wellness, and disease prevention." 14 The addition of a clinical pharmacist to the care of patients with CVD can lead to an improvement in CVD patients in many areas, including a reduction in CVD risk rates, optimizing CVD medications, improving patient knowledge and satisfaction, improving patient adherence, and preventing potential drug-related problems (DRPs). These improvements can lead to increased quality of life for CVD patients, reduced mortality rates, and decreased number of hospitalizations or emergency room (ER)/clinic visits. This, in turn, results in a decrease in total health care costs. 15, 16 Clinical pharmacists may participate in such services as patient education, medicine management, or both.
14 Previous systematic reviews conducted to measure the effect of clinical pharmacists on the direct care of patients with CVD have shown a positive impact on patient outcomes. [17] [18] [19] However, it is unknown if this impact would be seen in patients with established CHD or if it would result in a decrease or increase in health care costs. In this review, we aimed to evaluate the effectiveness of including clinical pharmacists in the treatment 
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nonanalytical or interventional studies, studies with no comparison group present, studies not conducted in the CVD therapeutic area, and systematic reviews or meta-analyses.
Study Selection
We screened the electronic search results and excluded irrelevant studies based on the exclusion criteria. The screening process was implemented to select potential studies included for the evaluation. This process was performed by 1 reviewer and checked for accuracy by another. The results of the screening step were then assessed by 2 reviewers who independently evaluated the studies' titles and abstracts. Full copies of studies accepted in the abstract assessment process were then retrieved and assessed independently by 2 reviewers. Any discrepancies were resolved by discussion, or if needed, a third reviewer was consulted.
Data Extraction and Study Quality Assessment
We extracted the studies included in this review by using a standardized data extraction form. The extraction process was performed by one of our reviewers and checked for accuracy by another. Quality assessment tools used in Jadad et al. (1996) 20 were used to assess RCTs, while the technique from Drummond et al. (2005) 21 was used to assess economic studies.
Data Analysis
Qualitative analyses were conducted to characterize the type of pharmacist services provided to patients and their effects on patient outcomes. Study outcomes were categorized into 4 groups: the CVD outcomes and mortality group (mortality, CHD risk, and HF); the CVD risk factor control group (controlling DM, hypertension, lipids, or cigarette smoking cessation); the patient outcomes group (patient adherence, knowledge, satisfaction, or quality of life); and the health care systems cost outcomes group (DRPs, hospitalization, length of hospital stay, ER/clinic visit, or direct). These outcomes were measured in each type of pharmacist-provided service, whether it was medicine management, educational intervention, or a combination of both.
■■ Results
Our search resulted in 2,665 studies after removing any duplication, from which 2,609 studies were found from the electronic search and 56 studies from searching other systematic reviews and meta-analyses' bibliographies and references. The initial screening excluded 2,462 studies, leaving a total of 203 studies. Title and abstract assessment of the remaining 203 studies resulted in the further exclusion of 108 studies. In the process of retrieving full copies of the studies, 14 studies were not obtainable and therefore not included. The full-copy assessment process resulted in the inclusion of 59 studies, of which 51 described clinical and cost outcomes, and 8 were full economic evaluations. Figure 1 illustrates the study selection process.
Clinical Studies
The majority of clinical studies measured pharmacist impact on CVD risk factor control. Fifteen studies were conducted to measure the impact of a clinical pharmacist in improving patients' DM, 12 in hypertension patients, 10 in hyperlipidemia patients, and 1 RCT in helping smoking patients to quit. One RCT and 1 cohort study were included in this review because they concerned the benefit of clinical pharmacists in improving DRPs associated with CVD risk factor control. The CVD risk factor control and DRP studies were conducted in inpatient, outpatient, and community settings. (Appendix B, available online) RCTs included in this review reported 116 different outcomes, which included mortality, CHD outcomes, HF outcomes, DM control, hypertension control, lipid control, smoking cessation, patient adherence, patient knowledge, patient satisfaction, quality of life, DRPs, hospitalization, length of hospital stay (LOS), ER/clinic visits, and direct costs. The 116 outcomes found in this review were measured as result of pharmacists providing medicine management intervention only (14), providing educational interventions only (44), or providing both types of intervention (58). When the outcomes 
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were categorized according to the setting, 62 outcomes were measured in outpatients settings, 51 in community settings, and 3 in inpatient settings. Table 1 summarizes the different types of outcomes and types of services provided by the pharmacists. Table 2 categorizes the reported outcomes according to the settings.
CVD and Mortality.
Eight RCTs reported improvement in CVD or mortality as 1 of their outcomes. Five out of 7 studies showed that clinical pharmacists have a statistical significant effect, while 2 studies showed no significant differences. The 2 studies that reported no significant differences in patient mortality were performed by providing educational intervention only. 22, 23 The other 5 studies reported statistical significant differences: 1 study measuring improvements in mortality and HF through medicine management only, 24 1 study measuring mortality after educational intervention only, 25 and 3 studies measuring improvement in CHD and HF by providing both types of service. 23, 26, 27 All the studies reporting outcomes related to CHD or HF control showed statistical significant improvement.
Risk Factor Control. Thirty-six RCT were found to report changes in CVD risk factors as 1 of their outcomes. In terms of DM control, 10 studies out of 14 reported statistically significant improvements with clinical pharmacist interventions. Of the studies demonstrating a significant difference, 1 intervention was medicine management only; 28 2 studies were educational interventions only; 29, 30 and 7 studies consisted of both types of services.
27,31-36 In terms of measuring the effect of pharmacist intervention on smoking cessation, only 2 studies were found that reported smoking cessation as one of their outcomes. One study of educational intervention found that there was a significant effect, while another study of both types of interventions reported no significant differences. 31, 37 In terms of controlling blood pressure, 20 studies out of 23 (86.9%) showed statistical significant effects of clinical pharmacist intervention. Of these studies, 1 performed medicine management (50%); 38 6 studies provided educational interventions (86%); 29,30,39-42 and 13 studies provided both types of intervention (93%). 26, 27, 31, [34] [35] [36] [43] [44] [45] [46] [47] [48] [49] In terms of controlling patients' lipid levels, 13 studies out of 20 (65%) showed a significant positive effect with the inclusion of a clinical pharmacist. 27, 29, 34, 42, [50] [51] [52] [53] [54] [55] [56] [57] [58] Patient Outcomes. We found 20 different studies that reported outcomes relating to patient knowledge, satisfaction, adherence, or quality of life. Twenty-two outcomes out of 31 (71%) were found to have statistical significant differences with clinical pharmacist intervention, while 9 of the outcomes showed no statistical significant difference. In terms of patient knowledge, 4 studies (80%) showed positive effects for clinical pharmacist intervention, 29,50,57,59 while 1 study showed no significant differences.
48 Educational intervention was performed in 3 different studies, and all of them reported significant positive differences for clinical pharmacist intervention. One study in which both types of services were provided showed statistical significant differences, while another study showed no significant effect. In terms of patient satisfaction, 5 out of 6 studies (83.3%) reported statistical significant positive outcomes with clinical pharmacist services. In 2 of the studies, pharmacists provided educational 
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intervention, and in the other 3, they provided both medicine management and educational intervention. 25, 43, 48, 49, 59, 60 One of the studies in which both services were provided showed no significant differences. In terms of patient quality of life, 7 out of 13 (53.8%) studies showed statistical significant effects for pharmacist intervention. 22, 23, 25, 26, 30, 43, 44, 48, 55, 58, 59, 61, 62 Two studies used educational intervention, and 5 studies provided medicine management and educational intervention. There was only 1 study in which just medicine management intervention was used, and it showed no significant differences.
Health Care Systems Cost. In our review, we found 16 studies that reported a total of 18 outcomes related to health care cost. These outcomes included DRPs, hospitalization, LOS, ER/ clinic visits, and direct costs. DRPs were reported in 4 studies, of which 1 study used medicine management intervention and 1 provided educational intervention; these showed statistical significant effects for clinical pharmacist intervention.
24,29
Two studies using both types of intervention showed no significant improvement. 36, 60 In terms of patient hospitalization, 1 study out of 3 that used educational intervention (33.3%) showed a statistical significant improvement. 22, 23, 25 No studies were conducted using medicine management or both types of intervention. In terms of LOS, we found only 1 study that used educational intervention and showed significant improvement. 25 In terms of the number of ER/clinic visits, 3 studies were carried out by providing both types of intervention. 36, 48, 56 One study showed positive effects in the clinical pharmacist group; another showed no significant differences; and 1 study showed significant differences in the control group. In studies reporting direct costs as one of their outcomes, there were 4 studies found to have significant effect with clinical pharmacist intervention (1 educational and 3 with both types of interventions provided). 40, 47, 56, 61 Three studies were conducted in outpatient settings and 1 in inpatient settings. Two studies reported lower costs in the intervention group through savings in medication costs, while 2 studies reported lower costs through savings in the total health care costs. Two studies using medicine management intervention failed to show any significant differences, while 1 study that performed both types of interventions showed statistical significant differences in the control group.
49,51,62
Economic Studies
We identified and included 8 economic studies in our review (Appendix C, available online). All of the economic studies were conducted as pharmacist-led interventions in community settings, except 1 that was conducted in an outpatient clinic. Three studies measured the economic impact of pharmacists in helping patients quit smoking; 2 studies involved patients with DM; and 1 study each addressed CHD, hyperlipidemia, and hypertension patients. Four economic studies were found to be cost-effectiveness analyses, while there was 1 each that addressed cost-benefit analysis, cost-utility analysis, costminimization analysis, and cost analysis. Three studies used an economic evaluation model, while 5 studies did not. In terms of helping patients quit smoking, 2 cost-effectiveness studies 68, 69 and 1 cost-utility analysis 70 found that using pharmacists to provide smoking cessation services resulted in a better use of health care resources. The same results were found with pharmacists providing interventions to improve DM control, Clifford et al. (2005) reported that pharmacists were able to improve blood pressure and DM control, which was reflected in a significant decrease in the total CHD risk.
35 Similar results were found by Varma et al. (1999) , who found that pharmacist intervention helped to decrease blood pressure, which was associated with an improvement in HF control, leading to a better score in patient quality of life measures. 26 The relationship between decreasing CVD risk factors and the improvement in CVD outcomes has been well established, and published clinical guidelines recommend an aggressive reduction in these risks.
Pharmacist intervention to improve patient outcomes such as patient satisfaction, adherence, and knowledge were found to lead to an improvement in CVD and patient quality of life. These results were found in 6 RCTs that showed improved patient outcomes were associated with an improvement in such CVD risk factors as blood pressure and lipid control.
42-44,50,61 Four RCTs found that this effect also extended to an hypertension, 72 and lipid control. 73 Only 1 study reported an increase in the use of health care resources, with no change in patient outcomes. 74 This study was a cost-minimization study conducted to measure improvement in CHD outcomes. Five studies looked at the health care system, while 2 studies used a societal approach, 68,72 and 1 study took a government perspective. 73 Four studies reported pharmacist services providing educational intervention; 1 study examined medicine management; and 3 studies reported on educational and medicine management interventions. None of the studies considered longer-term effects through using an economic model. Figure  2 describes the process relationships of interventions by which clinical pharmacists can help improve clinical and economic outcomes of CVD patient care. It shows that medicine management interventions have an influence in CVD management and CVD risk factor control and in reducing the number of DRPs. This may lead to better quality of life and less mortality and reduce the number of hospitalizations or ER/clinic visits, which will contribute to reducing health care costs. Further improvements were gained through educational interventions affecting patient knowledge, satisfaction, and adherence to medications.
■■ Discussion
The majority of outcomes reported in our review (68.6%) found that clinical pharmacy services were associated with 
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by improving various aspects of the process, including patient outcomes (knowledge, satisfaction, and adherence), CVD risk factor control, reducing the number of DRPs, and direct improvement in CVD control. These improvements may lead to an improvement in patient quality of life and mortality thus decreasing health care resources used. The quantity of this effect and its relation to the expected funds required to run such services is unknown. Because of deficiencies in current economic studies, further economic evaluations are required to assess the cost-effectiveness of clinical pharmacist intervention in patients with CVD.
improvement in patient quality of life. 43, 44, 50, 61 In 1 study, the effect of pharmacist intervention did not achieve significant changes in patient outcomes, and it was also associated with nonsignificant improvement in patient quality of life.
Pharmacist interventions to improve DRPs were associated with an improvement in CVD control and CVD risk factors. Gattis et al. (1999) 24 found that decreasing the number of DRPs in HF patients was associated with a decrease in HF events and mortality. Fornos et al. (2006) 29 found that a reduction in the number of DRPs was associated with an improvement in CVD risk factors. Both sets of results demonstrate the relationship between DRPs and improved care of patients with CVD, regardless of whether this benefit is realized through direct effects on CVD control and mortality or through better control of CVD risk factors. Patient quality of life was found to be affected by clinical pharmacist intervention through improving patient outcomes, CVD risk factor control, or both.
Studies evaluating the relationship between pharmacist intervention and health care costs showed that pharmacists can decrease total health care costs through improving CVD risk factor controls and patient outcomes. This may indicate that a reduction in health care costs by using pharmacist interventions is achieved from the positive impact they have in improving CVD or CVD risk factor outcomes. It also highlighted that pharmacist services that improve CVD or CVD risk factors may use fewer health care resources.
Considering the potential positive CVD outcomes and health care system savings associated with pharmacist interventions, it seems reasonable to conduct a full economic study to evaluate the cost-effectiveness of involving clinical pharmacists in the direct care of patients with CVD.
Limitations
This systematic review provided evidence of pharmacist benefits in the care of patients with CVD, although there are several limitations that affect the robustness of its conclusion. The review only includes published studies that are more likely to exist if positive outcomes emerge. It also included data from different settings and provided by different types of interventions, which may increase the level of heterogeneity of the results. The review only included 1 clinical study conducted in an inpatient setting, which makes the estimation of pharmacist effect in this setting less reliable. Furthermore, the economic studies found in this review that intended to measure the costeffectiveness of clinical pharmacist interventions with CVD patients had a number of limitations, including not providing a detailed explanation of pharmacist effect nor considering longer-term effects using economic modeling.
■■ Conclusion
Clinical pharmacist intervention can result in a significant improvement in CVD patient outcomes. This can be achieved (Pharmacy OR pharmacist* OR "pharmaceutical service" OR "pharmaceutical care") ➢ Step 2: Searched within the result of step 1 by using the following terms:
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(Cost* OR economic* OR cost-effectiveness OR cost-benefits OR cost-saving OR intervention* OR outcome* OR mortalit* OR morbidit*)
➢
Step 3: Limited the result of step 2 with the following topics:
"pharmaceutical care, health care ,medicare, ambulatory care, care service, patient satisfaction, pharmacy practice, pharmaceutical outcome, pharmaceutical service, pharmaceutical therapy"
Database of Abstracts of Reviews of Effectiveness (DARE)
➢ DARE database was searched by using the NHS searching engine. This search is discussed in further detail in step 5.
Health Technology Assessment Database (HTA)
➢ HTA database was searched by using the NHS searching engine. This search discussed in further detail in step 5. 
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The following trial registries were searched to identify any further completed and published trials: 
This includes body mass index (P < 0.001), fasting blood glucose (P < 0.001), HbA1c (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P < 0.001), total cholesterol (P < 0.001), HDL (P < 0.001), LDL (P < 0.001), and triglycerides (P < 0.001).
Framingham risk scores were also improved in the intervention group (P < 0.001) and remained unchanged in the control group.
3
The Patients in the intervention group achieved a greater decrease in HbA1c than those in the control group (P = 0.03). Intervention group patients also had more frequent examinations than the control group. This included LDL (P = 0.02), retinal examination (P = 0.004), and foot examination (P = 0.002). No significant differences were found between the 2 groups in terms of changes in HbA1c measurements (P > 0.2). Same results were found in terms of quality of life (P > 0.15). In patient satisfaction survey, the intervention group had greater satisfaction with the service provided by the clinical pharmacist (P = 0.007) and better drug information satisfaction (P = 0.036).
The study concluded that the pharmacist had no impact on patients' glycemic control over short period of time. 
The study found that using a recommendation letter to provide pharmacist intervention had no effect in diabetic care. Patients in the intervention group had more improvement in many outcomes than those in the control group. These include DRP (P < 0.0001), knowledge (P < 0.0001), HbA1c (P < 0.0001), fasting blood glucose (P = 0.0004), total cholesterol (P = 0.0054), and systolic blood pressure (P = 0.0006). The intervention group had a larger decrease in mean HbA1c compared with the control group (P = 0.06). This improvement was found to be more significant in male (P = 0.3) and white patients (P = 0.05). For patients with a reduction of 1% or more in HbA1c, the intervention group had a significant number of patients compared with the control group (P = 0.02).
CVD = cardiovascular disease; HbA1c = hemoglobin A1c.
Randomized Controlled Trials Conducted in an Outpatient Setting Using a Pharmacist-Led Intervention Model for Patients with Diabetes Mellitus
3
The study concluded that using a clinical pharmacist can significantly improve patients' glycemic control in community setting. Results showed no significant differences between the 2 groups in terms of HbA1c (P = 0.56). The intervention group had a significant improvement in total cholesterol reduction (P < 0.0001), LDL reduction (P = 0.002), HDL increase (P = 0.06), and patient knowledge of diabetes (P = 0.002). The study showed that both groups had significant improvement in HbA1c (P = 0.003) with more improvement in the intervention group (P < 0.05). The intervention group also had more improvement in LDL level (P = 0.012) and systolic blood pressure (P = 0.023). Patients in the intervention group had more improvement in fasting serum glucose (P < 0.001), HbA1c (P = 0.002), systolic blood pressure (P = 0.024), and diastolic blood pressure (P = 0.043). No significant differences were found in total cholesterol (P = 0.14), HDL (P = 0.07), or triglycerides (P = 0.09). The estimated risk of first CHD events decreased more in the intervention group (P = 0.002). There were no significant differences found between the intervention group and the control group in terms of changes in HbA1c, LDL, or blood pressure. The pharmacist helped patients to increase their engagement with diet (P = 0.001) and diabetic self-activity (P = 0.027). The intervention group had significant changes in HbA1c (P < 0.01), systolic blood pressure (P=0.06), and quality of life (EQ-5D; utility score P = 0.07, health state scale P = 0.02).
DRP = drug-related problem; HbA1c = hemoglobin A1c.
Randomized Controlled Trials Conducted in a Community Setting Using a Pharmacist Collaborative Model for Patients with Diabetes Mellitus
There were no significant differences in BMI, diastolic blood pressure, total cholesterol, and triglycerides. Patients treated in the intervention group had more significant changes in their blood pressure than the control group. This included daytime systolic blood pressure (P < 0.001), nighttime systolic blood pressure (P = 0.004), overall 24-hour systolic blood pressure (P < 0.001), at office systolic blood pressure (P < 0.001), daytime systolic blood pressure (P < 0.001), overall 24-hour diastolic blood pressure (P < 0.001), at office diastolic blood pressure (P < 0.001). No significant differences were found in nighttime diastolic blood pressure (P = 0.12).
Randomized Controlled Trials Conducted in a Community Setting Using a Pharmacist-Led Intervention Model for Patients with Diabetes Mellitus
Randomized Controlled Trials Conducted in an Outpatient Setting Using a Pharmacist Collaborative Model for Patients with Hypertension
3
The study showed that the collaboration of pharmacist and physician resulted in more reduction in blood pressure and more patients with controlled blood pressure levels. Both groups showed significant reduction in blood pressure with a greater decrease in the intervention group (P < 0.01). More patients were found to achieve target blood pressure in the intervention group than in the control group (P = 0.02). Patients in the intervention group had a lower average visit cost per patient than the control group (P = 0.02) and lower average primary care visits (P < 0.01).
2
The use of pharmacist-physician collaboration improved blood pressure control and decreased average clinic visits. Guideline adherence score increased in the intervention group more than in the control group (P = 0.09). The mean blood pressure was also reduced in the intervention group more than in the control group (P < 0.05) with the same effect found in 24-hour measurements. More patients achieved controlled blood pressure in the intervention group (P < 0.001).
Randomized Controlled Trials Conducted in an Outpatient Setting Using a Pharmacist Collaborative Model for Patients with Hypertension (continued)
3
A better mean blood pressure was achieved by pharmacist-physician collaboration. The authors recommended to investigate teambased chronic disease management strategies.
Carter, 2008 67
United States
The pharmacist assessed the patients, suggested a blood pressure goal, and recommended any changes required to improve blood pressure control. Also, a pharmacist was involved in patient education and encouraged adherence. The percentage of hypertension patients who had controlled blood pressure were higher in the intervention group than in the control group (P < 0.001). This included diabetic patients (P = 0.002) and nondiabetic patients (P < 0.001). Patients in the intervention group had better reduction in both systolic (P = 0.007) and diastolic blood pressure (P = 0.002). This resulted in more patients achieving their target blood pressure in the intervention group than in the control group (P=0.003). In term of utilization, patients in the intervention group had a higher number of office visits (P < 0.0001) and a lower number of physician visits (P < 0.0001). There were no significant differences found between the 2 groups in terms of hypertension knowledge, medication adherence, quality of life, or patient satisfaction.
3
The involvement of pharmacists in the management of hypertension patients improved blood pressure control without increasing the cost, complexity of the drug regimen, or altering patients' quality of life. Patients in the intervention group had a significant reduction in systolic blood pressure at 2, 3, 4, 5, and 6 months (P < 0.001) compared with baseline. They also had significant reduction in diastolic blood pressure at 2, 4, and 5 months (P < 0.05) and at end of study (P = 0.054) from baseline. Patients in the control group did not show any significant changes. Patients in the intervention group also had significant improvements in quality of life scores and patient satisfaction after 6 months, whereas the control group did not have significant changes. In terms of total mean changes, the intervention group was higher than the control group (P = 0.006).
Randomized Controlled Trials Conducted in an Outpatient Setting Using a Pharmacist Collaborative Model for Patients with Hypertension (continued)
3
Patients monitored by community pharmacist had more improvement in blood pressure control, quality of life, and patient satisfaction measured. The rate of patients achieving target LDL level in the intervention group was double the rate of those in the control group (43% vs. 21%, P < 0.05). In subgroup analysis, it was found that pharmacist intervention was more significant in patients with CHD (P < 0.01) or with 2 or more risk factors (P < 0.05) while no significances were detected in patients without CHD or with less than 2 risk factors. In the last month of the study, medication charges decreased by $11.40 per patient in the intervention group, while it increased by $3.82 in the control group, but the difference was not statistically significant. More clinic visits were found in the intervention group than in the control group (P < 0.05).
Randomized Controlled Trials Conducted in a Community Setting Using a Pharmacist Collaborative Model for Patients with Hypertension
3
Managing high risk patients by using pharmacist-physician collaboration had better outcomes than using standard care alone. Patients in the intervention group had a greater reduction in their LDL (P < 0.001), total cholesterol (P < 0.001), and triglycerides levels (P = 0.022). They also had better improvement in their HDL levels (P = 0.03).
3 Pharmacistphysician collaboration was an effective method to achieve target cholesterol level. Pharmacists contacted patients by phone to review their annual full lipid profiles, blood pressure measurements, and medication adherence; provided counseling on diet and exercise regimens; and made medication adjustments to maintain treatment goals. A pharmacist also ordered follow-up laboratory tests, mailed patients their results, and scheduled lipid follow-ups. (214 patients)
CHD = coronary heart disease; HDL = high-density lipoprotein; LDL = low-density lipoprotein.
Randomized Controlled Trial Conducted in a Community Setting Using a Pharmacist-Led Intervention Model for Patients with Hypertension Randomized Controlled Trials Conducted in a Community Setting Using a Pharmacist-Led Intervention Model for Patients with Hypertension
Patients were discharged from the pharmacist service and continued to receive the usual care. (207 patients) Study showed that individuals who were discharged from clinical pharmacist services continued to have controlled blood lipids and blood pressure with no significant differences between the 2 groups: LDL-C goal: < 100, P = 0.46, and < 70 mg/dL, P = 0.23; blood pressure goal: < 140/90 mmHg, P = 0.03 and <130/80 mmHg, P = 0.71.
3
Patients discharged from pharmacist services after controlling their lipids and blood pressure can continue under control with minimal follow-up. The intervention group had significant changes in many laboratory outcomes including total cholesterol (P = 0.0001), LDL (P = 0.0001), HDL (P > 0.05), and triglycerides (P = 0.009). The intervention group also had significant improvements in their quality of life compared with the control group (P < 0.001).
The study showed that pharmacist care program improved patients' lipid control, CVD risk, and quality of life.
Ellis, 2000 75
Pharmacists provided medication assessments and applied any changes when required. They also followed up with patients and monitored responses until desired goals were achieved. (208 patients)
Control group did not receive any intervention from a pharmacist.
(229 patients)
Patients in the intervention group were found to have greater fasting lipid profiles than the control group (P = 0.021). They also showed more improvement in their total cholesterol (P = 0.028) and LDL (P = 0.042). No significant differences were found in terms of patients reaching goal lipid measurements or overall costs.
3
Pharmacist can improve LDL and total cholesterol significantly without increase of overall health care cost. Significant differences were found in this study in favor of the intervention group (P < 0.001) in terms of improvement of cholesterol management. Patients in the intervention group also had better outcomes in subgroup analysis, which included women (P < 0.001), men (P < 0.001), age < 70 (P < 0.001), age ≥ 70 (P < 0.001), urban pharmacy practice (P < 0.001), rural pharmacy practice (P = 0.07), diabetic patients (P < 0.001) and nondiabetic patients (P < 0.001). The pharmacist intervention group had a significant reduction in average blood cholesterol levels (P = 0.0266) and triglyceride levels (P = 0.0169); in the control group, patients had a nonsignificant reduction in cholesterol levels (P = 0.6624) and slightly increased triglyceride levels (P = 0.1435). The difference in patient quality of life was higher at the end of the study in favor of the pharmacist intervention group (P = 0.002). The pharmacist intervention group had a significant reduction in total cholesterol from baseline (P < 0.005), while the control group had no significant changes (0.26). At the end of the study, the number of patients with a controlled cholesterol level (< 4.0 mmol/L) was higher in the intervention group (P = 0.06).
CVD = cardiovascular disease; HDL = high-density lipoprotein; LDL-C = low-density lipoprotein cholesterol; mg/dL = milligram per deciliter; mmHg = millimeter mercury.
Randomized Controlled Trials Conducted in an Outpatient Setting Using a Pharmacist-Led Intervention Model for Patients with Hyperlipidemia
Randomized Controlled Trial Conducted in a Community Setting Using a Pharmacist Collaborative Model for Patients with Hyperlipidemia
3
Pharmacists had a useful role in reducing morbidity and mortality associated with CHD in the community. This effect may double the benefits obtained from usual care. Smokers in the intervention group had a significantly higher number of individuals who were abstinent for up to 12 months (P < 0.001).
CHD = coronary heart disease; CVD = cardiovascular disease; HDL = high-density lipoprotein; mmol/L = millimole per liter.
Randomized Controlled Trials Conducted in a Community Setting Using a Pharmacist-Led Intervention Model for Patients with Hyperlipidemia
3
The structured pharmaceutical care for smoking cessation is an effective model, but questions remain about the proportion of pharmacists willing to be involved in this service. Patients in the intervention group had a significant reduction in their systolic blood pressure (P = 0.007), diastolic blood pressure (P = 0.005), HbA1c (P = 0.02), and use of aspirin (P<0.0001). There were no significant changes found in total cholesterol measurements (P = 0.35), use of clinical services, or potential adverse events. The overall adherence to standard guidelines was good in both groups, with no significant differences except for antiplatelet prescribing (P = 0.076). There were no differences between the 2 groups in terms of quality of life and costs, without including pharmacist time costs for all patients. When the pharmacist time costs were included, a significant difference was found in favor of the control group (P < 0.001).
Randomized Controlled Trial Conducted in a Community Setting Using a Pharmacist-Led Intervention Model for Smokers
3
Benefits measured in the intervention group were small, and it was less than other studies measurement. This benefit was combined with minimal changes in prescribing, and the cost of the pharmacist group was higher without measuring pharmacist time cost. No significant differences were found between the 2 groups in terms of aspirin prescribed, lifestyle measures, lipid management, blood pressure, smoking, or alcohol use. The intervention group had a better result in terms of patient satisfaction (P < 0.01) with a higher total National Health Service cost (P < 0.0001).
Randomized Controlled Trial Conducted in a Community Setting Using a Pharmacist Collaborative Model for Patients with Coronary Artery Disease
3
The community pharmacist did not significantly improve the proportion of patients receiving appropriate medication, and it was more expensive. Patients in the intervention group had a lower rate of all the causes of mortality and heart failure events compared with the control group (P = 0.005). Intervention group patients also had significantly higher angiotensin enzyme inhibitor (ACE I) doses than those in the control group (P < 0.001), with a higher use of other vasodilators in patients with ACE I intolerance (P = 0.02).
Randomized Controlled Trial Conducted in a Community Setting Using a Pharmacist-Led Intervention Model for Patients with Coronary Artery Disease
3
The study found that the clinical pharmacist is an important member of the multidisciplinary heart failure team and significantly improves patient care.
Varma, 1999 26
United Kingdom
Pharmacists discussed with physicians the appropriateness of drug therapy and educated patients for better self-care. (42 patients)
Patients received usual standard care.
(41 patients)
Patients in the intervention group showed more improvement in a 2-minute walking test (P = 0.03) and blood pressure (P = 0.01). The intervention group also had more improvement in some components of quality of life tests, including physical functioning (P < 0.05), vitality (P < 0.05), social functioning (P < 0.05), and mental health (P < 0.05). No significant differences between the 2 groups were found in term of forced vital capacity or pulse control. Patients in the intervention group did not have a significant decrease in the number of admissions (P = 0.28) or death (P = 0.54). In terms of quality of life, Eq-5D showed a better result for the intervention group while the Minnesota Living with Heart Failure Questionnaire showed a better improvement in the control group. None of these quality of life measure differences were significant.
3
Community pharmacist interventions did not improve heart failure outcome and reduce readmission rates. At the end of phase 1, patients had significant improvements in medication adherence (P < 0.001), systolic blood pressure (P = 0.02), and LDL levels from baseline (P = 0.001).
Randomized Controlled Trials Conducted in a Community Setting Using a Pharmacist-Led Intervention Model for Patients with Heart Failure
After stopping the services for the control group, patients in the intervention group had a significant difference in medication adherence and systolic blood pressure. Patients receiving intervention from clinical pharmacists had significant improvements in HbA1c and blood glucose (P ≤ 0.001). They also had improvement in the number of emergency room visits, which resulted in decreased costs (P = 0.015).
Pharmacist interventions under agreed protocol significantly improved diabetic patient control. This was combined with significant reduction in hospitalization and emergency room visits. Baseline measurements for patients included in the study were used as a control.
Patients who received direct care from a clinical pharmacist had significant improvements in HbA1c concentration, especially in the first 2 follow-up visits (P < 0.0001). A significant reduction was also found in LDL levels at the second follow-up visit and HDL at the third follow-up visit (P = 0.05). Total mean drug costs were reduced per patient per year from baseline by $1,200 to $1,872.
Pharmacist interventions improved diabetic patient control with a decline in total medical cost during each year of follow-up. Patients with high levels of HbA1c were most likely to have benefits from these interventions. Pharmacists reviewed patient medical records; obtained medical and drug histories; assessed patient specific drug issues; assessed compliance and patient knowledge about hypertension and lifestyle modification; monitored patient drug therapy; and discussed with physicians drugrelated problems or any changes required.
Nonrandomized Controlled Trials Conducted by Using a Pharmacist-Led Intervention Model for Patients with Diabetes Mellitus and Reporting Cost
Control group received usual care without any intervention from a pharmacist related to pharmaceutical care.
Patients in the intervention group had a significant decrease in their blood pressure compared with baseline in both systolic (P = 0.001) and diastolic blood pressure (P = 0.01). Patients in the control group did not have any significant differences in their blood pressure. When the changes in the 2 groups were compared, the only significant difference was found in systolic blood pressure (P = 0.05). There were no significant differences found in quality of life (SF-36) except in physical activity (P = 0.03). 
United States
Pharmacists sent letters to physicians regarding patient cholesterol, which included pharmacist recommendations. Pharmacists then made telephone follow-ups to confirm the application of these recommendations and achievement of target levels.
Patients in the control group did not receive any pharmacist recommendations.
Patients in the intervention group had a significantly higher level of statin use, clinic visits, and laboratory tests, which were reflected in a significantly higher number of patients achieving the target LDL level. The total cost for the intervention group was lower than for the control group ($1,576,898 vs. $1,968,674).
Concludes that pharmacist-made recommendation to physicians regarding statin therapy for patients with CHD was associated with an improvement in statin use, better LDL levels, and cost saving. 
CHD = coronary heart disease; LDL = low-density lipoprotein.
Nonrandomized Controlled Trial Conducted in an Outpatient Setting Using a Pharmacist Collaborative Model for Patients with Hyperlipidemia and Reporting Cost
United States
Pharmacists assessed patient adherence and educated patients regarding their condition, medication administration, role of medication, nondrug therapy, self-monitoring, and adverse effects. Pharmacists also assessed patient blood pressure, cholesterol determinations, blood glucose, and peak flow rate, weight, pulse, and respiratory rate. All information obtained by pharmacists was documented and regularly sent to patient's physician by letter or phone. Any recommendations or referrals required were included in the letters.
Patients did not receive any intervention from a pharmacist.
The study showed no significant differences between the 2 groups in terms of monthly prescription costs, except for patients with asthma (P = 0.03). For overall costs, pharmacist intervention resulted in significant differences from the control group (P = 0.024).
Pharmacist intervention can play an important role in decreasing health care cost, although this study showed a higher average of cost per prescription in the intervention group than the control group. This difference was not statistically significant except for patients with asthma. The average monthly medical costs were reduced in the intervention group, and pharmacist intervention was shown to reduce overall health care costs. Pharmacists gave detailed advice depending on the smoker cessation stage with appropriate follow-up.
Nonrandomized Controlled Trial Conducted in a Community Setting Using PharmacistLed Intervention Model for Patients with Drug-Related Problems and Reporting Cost
Pharmacists provided medication review and documented any recommendations made for each patient.
Description of control
Patients in the control group did not have a structured interview with a pharmacist.
Patients received written material with general information about CVD risk factors with minimal follow-up.
Pharmacists gave standard advice and support for smoking cessation.
Patients received the standard of care as normal. Prospective, concurrent collection of costs and effects data.
Source of effectiveness data
Data relating to cost and effectiveness was collected prospectively and concurrently.
Clinical outcomes measured and methods of valuation used
Outcomes measured in another study in term of medicine management and improving CHD patients' outcomes (nonsignificant).
Outcomes measured in terms of changes in cardiovascular risk by using the Framingham risk score.
Outcomes measured in term of quitters at 9 months.
Clinical outcomes measured in term of changes in HbA1c and glucose levels.
Comments
Suitability of CMA questionable.
Unconvincing study: authors have undertaken a "cost-identification" analysis assuming that improvement in risk factor management would translate into reduction in CV risk. Would need an improved study to make such a case.
A relatively old and limited study that highlighted contributions made by clinical pharmacists in achieving a cost-effective cessation in smoking.
Would have benefited from patient-level data and probabilistic sensitivity analysis and consideration of longer-term scenarios via modeling.
Authors' conclusions
The 1-year pharmacist-led medicine management was associated with a total cost increase with no changes in patient outcomes. The use of health care resources is unlikely to be efficient in this particular service.
Clinical pharmacy services in community were shown to be effective in terms of improving cholesterol management, systolic blood pressure, and reduction of the 10-year risk of CVD with a minimal increase in the incremental cost to the government health care system.
The study provided evidence of the community pharmacist costeffectiveness in delivering smoking cessation advice to achieve national targets.
The study showed a significant reduction of HbA1c in favor of the intervention group at a cost of $A 383. It is likely to produce a cost saving to health care in the long term. 
Prospective and concurrent
Clinical outcomes measured and methods of valuation used
Probability of events was used to assess the efficacy of the smoking cessation program.
Outcomes measured in terms of changes in numbers of quitters.
Outcomes measured in terms of quitters at 9 months.
Outcomes measured in terms of blood pressure, cholesterol levels, CHD 10-year risk, and CVA 10-year risk.
Comments
Highlights other decision factors.
Good CUA -albeit without PSA.
CBA using WTP -useful as approach.
Very limited explanation and discussion of costeffectiveness.
Authors' conclusions
Pharmacy program for smoking cessation was found to be cost saving and provided a gain in life years.
Both the pharmacy smoking cessation program and smoking cessation support group are considered to be very cost effective. A longterm study will be required to assess lifetime costeffectiveness.
Pharmacist program seems promising in terms of improving patient blood pressure. This conclusion will require further research in order to be confirmed.
The study resulted in a significant reduction of CVA and CHD risk in diabetic patients in the intervention group. 
CBA = cost benefits analysis
